Adviser, broker charged by SEC with insider trading

King Pharmaceuticals-Pfizer deal led to nearly $500,000 in illegal profits, agency claims.
SEP 25, 2013
New York financial adviser Tibor Klein and a friend, a Florida broker, earned more than $437,000 in illegal profits for themselves and clients by trading shares of King Pharmaceuticals after they were tipped that the drug firm would be purchased by giant Pfizer Inc., securities regulators said Friday. The Securities and Exchange Commission alleged that Mr. Klein, president of Klein Financial Services, began purchasing King Pharmaceuticals shares on the first trading day after he learned about the merger from a client who does legal work for the company. After the merger was announced Oct. 12, 2010, the stock's price rose 39% and Mr. Klein sold shares in his and in clients' accounts to generate profits of $328,375, the SEC said in its complaint. Mr. Klein also tipped his best friend Michael Shechtman, a stockbroker who lives in Florida, after learning about the deal, the SEC said. Mr. Shechtman then purchased shares and options in his and his wife's accounts, the commission said. Mr. Shechtman sold those shares and options after the deal was announced and shares rose, earning him about $109,040 in illegal profits, according to the complaint filed in the U.S. District Court for the Southern District of Florida. “As securities industry professionals, Klein and Shechtman clearly know the difference between legal and illegal trading,” said Eric I. Bustillo, director of the SEC regional office in Miami. “Instead of playing by the rules, they chose to exploit nonpublic information for an easy payday, but they didn't plan on getting caught by the SEC.” Neither Mr. Klein's lawyer, Tucker Byrd, nor Mr. Shechtman's lawyer, Jim Sallah, returned calls seeking comment. The SEC said there were many more calls than normal between the two friends over the days involved. The complaint also said that Mr. Shechtman had never traded in options before the trades noted in this case.

Latest News

The 2025 InvestmentNews Awards Excellence Awardees revealed
The 2025 InvestmentNews Awards Excellence Awardees revealed

From outstanding individuals to innovative organizations, find out who made the final shortlist for top honors at the IN awards, now in its second year.

Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty
Top RIA Cresset warns of 'inevitable' recession amid tariff uncertainty

Cresset's Susie Cranston is expecting an economic recession, but says her $65 billion RIA sees "great opportunity" to keep investing in a down market.

Edward Jones joins the crowd to sell more alternative investments
Edward Jones joins the crowd to sell more alternative investments

“There’s a big pull to alternative investments right now because of volatility of the stock market,” Kevin Gannon, CEO of Robert A. Stanger & Co., said.

Record RIA M&A activity marks strong start to 2025
Record RIA M&A activity marks strong start to 2025

Sellers shift focus: It's not about succession anymore.

IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients
IB+ Data Hub offers strategic edge for U.S. wealth advisors and RIAs advising business clients

Platform being adopted by independent-minded advisors who see insurance as a core pillar of their business.

SPONSORED Compliance in real time: Technology's expanding role in RIA oversight

RIAs face rising regulatory pressure in 2025. Forward-looking firms are responding with embedded technology, not more paperwork.

SPONSORED Advisory firms confront crossroads amid historic wealth transfer

As inheritances are set to reshape client portfolios and next-gen heirs demand digital-first experiences, firms are retooling their wealth tech stacks and succession models in real time.